BGAI
REGN icon

Bruce G. Allen Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Bruce G. Allen Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3K Sell
31
-2
-6% -$1.36K 0.01% 417
2026
Q1 		$25.5K Hold
33
– – 0.02% 362
2025
Q4 		$25.5K Buy
33
+1
+3% +$679 0.02% 365
2025
Q3 		$18K Sell
32
-4
-11% -$2.26K 0.01% 417
2025
Q2 		$18.9K Sell
36
-4
-10% -$2.23K 0.01% 404
2025
Q1 		$25.4K Sell
40
-6
-13% -$4.13K 0.02% 357
2024
Q4 		$32.8K Buy
46
+13
+39% +$10.9K 0.03% 315
2024
Q3 		$34.7K Sell
33
-9
-21% -$10K 0.03% 316
2024
Q2 		$44.1K Buy
42
+5
+14% +$4.85K 0.04% 261
2024
Q1 		$35.6K Sell
37
-8
-18% -$7.61K 0.03% 297
2023
Q4 		$39.5K Buy
+45
New +$37.1K 0.04% 277

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bruce G. Allen Investments's REGN Position: Q2 2026 in Review

Bruce G. Allen Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 6.1% in Q2 2026, selling an estimated $1.36K and leaving 31 shares worth $19.3K. The position accounts for 0.01% of the portfolio, ranked #417.

Bruce G. Allen Investments first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $44.1K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Bruce G. Allen Investments held 31 shares of Regeneron Pharmaceuticals worth $19.3K as of Q2 2026.
  • Bruce G. Allen Investments sold 2 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.36K.
  • Regeneron Pharmaceuticals made up 0.01% of Bruce G. Allen Investments's portfolio in Q2 2026, its #417 holding.
  • Bruce G. Allen Investments first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Bruce G. Allen Investments's Regeneron Pharmaceuticals position peaked at $44.1K in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bruce G. Allen Investments's 13F filing for Q2 2026, filed 31 Jul 2026.